### Amphotericin B

**Section:** 6. Anti-infective medicines  >  6.3. Antifungal medicines

#### Indication
- **Aspergillosis**
- **ICD11 code:** 1F20.Z

#### INN
- Amphotericin B

#### Medicine type
- Chemical agent

#### List type
- Core (EML)
- (EMLc)

#### Additional notes
- *Liposomal amphotericin B has a better safety profile than the sodium deoxycholate formulation and should be prioritized for selection and use depending on local availability and cost.*

#### Formulations
- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex);
- 50 mg in vial powder for injection (as sodium deoxycholate)

#### EML status history
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2013 (TRS 985)
- Changed in 2023 (TRS 1049)

#### Sex
- All

#### Age
- Also recommended for children

#### Therapeutic alternatives
- The recommendation is for this specific medicine

#### Patent information
- Patents have expired in most jurisdictions
  - [Read more about patents.](#)

#### Wikipedia
- [Amphotericin B](#)

#### DrugBank
- [Amphotericin b](#)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.